Gothenburg, Sweden month 2023 – VERIGRAFT announced today that Dr Petter Björquist, CEO of VERIGRAFT will present at the annual Cell & Gene Meeting on the Med to be held April 12-14 in Barcelona, Spain and livestreamed globally.
VERIGRAFT is a biotechnology company based in Gothenburg, Sweden. The company was founded in 2014, rooted in the Karolinska Institute and based on groundbreaking basic science.
VERIGRAFT has grown to become a forerunner in industrialized tissue engineering and advanced regenerative medicine. The company has a strategically focused R&D pipeline of personalized tissues, targeting areas such as cardiovascular and neuronal disease. VERIGRAFT will commercialize a series of personalized tissue-engineered grafts on a global market. Current and future products will help millions of patients with today uncurable diseases, severely impacting quality of life and putting numerous patiens out of work or into disability programs.
VERIGRAFT’s headquarters are located close to Gothenburg University and Sweden’s biggest university hospital in central Gothenburg. Here the company has state-of-the-art preclinical laboratories and offices. VERIGRAFT is led by a team of experienced scientists and entrepreneurs, and is backed by investors from Europe, Asia and the US.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Med is a two-day conference featuring more than 60 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.
The following are specific details regarding VERIGRAFT’s presentation at the conference:
Event: 2023 Cell & Gene Meeting on the Med
Date: Thursday, April 13, 2023
Time: 3:30 PM in the Gaudi 2 Ballroom